Share Price and Basic Stock Data
Last Updated: February 9, 2026, 9:33 pm
| PEG Ratio | -10.74 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Thyrocare Technologies Ltd, operating within the Hospitals & Medical Services industry, reported a share price of ₹396 and a market capitalization of ₹6,302 Cr. The company demonstrated a robust sales trajectory, with revenues for the trailing twelve months (TTM) reaching ₹708 Cr. Sales figures have shown consistent growth, with quarterly sales increasing from ₹117 Cr in December 2022 to ₹136 Cr by September 2023. The company’s annual sales have also trended positively, increasing from ₹562 Cr in March 2022 to ₹524 Cr in March 2023, before anticipated growth to ₹633 Cr in March 2025. The operating profit margin (OPM) has remained stable, averaging around 30%, indicating effective cost management. Despite a slight dip in sales in the March 2023 quarter, the overall sales growth trend is evident, showcasing Thyrocare’s resilience in a competitive healthcare landscape. The company’s strategic positioning and operational efficiency have allowed it to capture market share effectively in the diagnostic services sector.
Profitability and Efficiency Metrics
Thyrocare Technologies Ltd’s profitability metrics underline its operational efficiency, with a reported return on equity (ROE) of 17.4% and return on capital employed (ROCE) at 26.5%. The net profit for the last fiscal year stood at ₹57 Cr, reflecting a solid recovery from ₹15 Cr in December 2023. The company recorded an impressive interest coverage ratio of 67.28x, showcasing its strong ability to meet interest obligations. The operating profit margin (OPM) stood at 32%, which is significantly higher than the industry average, indicating superior operational efficiency. Thyrocare’s cash conversion cycle (CCC) was notably efficient at -9 days, suggesting a fast turnover of working capital. The company reported a net profit margin of 13.41% for March 2025, reflecting effective cost control measures. However, the fluctuating quarterly profits, particularly a decline to ₹10 Cr in March 2023, raise concerns about the sustainability of profitability in the face of variable income streams.
Balance Sheet Strength and Financial Ratios
As of March 2025, Thyrocare Technologies Ltd exhibited a strong balance sheet with total assets of ₹676 Cr, supported by reserves of ₹484 Cr and minimal borrowings of ₹23 Cr. This positions the company with a low debt-to-equity ratio, reinforcing its financial stability. The current ratio stood at 2.77, indicating a strong liquidity position, while the quick ratio of 2.39 further supports this assertion. The price-to-book value (P/BV) ratio is reported at 6.59x, reflecting a premium valuation in the market compared to sector peers. The company’s equity capital has remained stable at ₹53 Cr, while its retained earnings have been under pressure, evidenced by a negative earnings retention ratio of -4.15%. However, the interest coverage ratio indicates a strong capacity to service debt, while the asset turnover ratio of 1.03 suggests efficient use of assets to generate revenue. This financial strength could be attractive for potential investors looking for stability in the healthcare sector.
Shareholding Pattern and Investor Confidence
Thyrocare’s shareholding pattern reveals a strong promoter stake of 60.93% as of December 2025, down from 71.14% in March 2023, indicating a gradual dilution of control. Institutional investors hold a combined stake of 25.48%, with foreign institutional investors (FIIs) at 5.32% and domestic institutional investors (DIIs) at 20.16%. The public shareholding stands at 13.58%, reflecting a diverse ownership structure. The significant increase in the number of shareholders to 77,969 by December 2025 points to growing investor interest in the company. However, the decline in promoter holdings may raise concerns about long-term commitment. The fluctuation in FIIs and DIIs shareholding also suggests varying investor confidence in Thyrocare’s growth prospects. This dynamic could affect the stock’s liquidity and price stability in the market, making it essential for the company to maintain investor relations and transparency.
Outlook, Risks, and Final Insight
Thyrocare Technologies Ltd presents a mixed outlook with notable strengths and inherent risks. Strengths include its strong financial metrics, efficient operations, and a solid market position in the diagnostic services sector. The low debt levels enhance its financial stability and operational flexibility. However, risks such as fluctuating profit margins, reliance on a limited product range, and changes in regulatory environments could impact future performance. Additionally, the recent decline in promoter shareholding may raise questions about corporate governance and long-term strategy. To mitigate these risks, Thyrocare must focus on diversifying its service offerings and enhancing customer engagement. The company is well-positioned to capitalize on the growing demand for healthcare services, particularly in diagnostics, but must navigate these challenges effectively to sustain growth and deliver value to shareholders.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 47.9 Cr. | 143 | 187/120 | 9.78 | 117 | 2.45 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 14.2 Cr. | 13.5 | 33.0/13.1 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.3 Cr. | 9.99 | 20.5/7.08 | 18.7 | 0.00 % | 3.00 % | 0.81 % | 10.0 | |
| Fortis Malar Hospitals Ltd | 103 Cr. | 55.2 | 98.7/52.2 | 22.8 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.0 Cr. | 3.52 | 6.30/3.28 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 25,600.14 Cr | 689.29 | 88.70 | 92.86 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 117 | 125 | 124 | 136 | 123 | 141 | 144 | 163 | 153 | 174 | 179 | 202 | 182 |
| Expenses | 91 | 102 | 90 | 100 | 92 | 108 | 101 | 114 | 112 | 118 | 122 | 133 | 124 |
| Operating Profit | 26 | 23 | 33 | 37 | 31 | 34 | 42 | 49 | 40 | 56 | 57 | 69 | 58 |
| OPM % | 22% | 18% | 27% | 27% | 25% | 24% | 29% | 30% | 26% | 32% | 32% | 34% | 32% |
| Other Income | 1 | 2 | 0 | 2 | 2 | 3 | 3 | 2 | 4 | 5 | 4 | 2 | -3 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | -0 |
| Depreciation | 9 | 9 | 9 | 9 | 11 | 10 | 9 | 10 | 15 | 12 | 9 | 10 | 20 |
| Profit before tax | 18 | 15 | 24 | 28 | 21 | 25 | 35 | 40 | 28 | 48 | 51 | 61 | 37 |
| Tax % | 28% | 33% | 31% | 28% | 28% | 23% | 28% | 27% | 32% | 54% | 29% | 29% | 29% |
| Net Profit | 13 | 10 | 17 | 20 | 15 | 19 | 25 | 30 | 19 | 22 | 36 | 43 | 26 |
| EPS in Rs | 0.80 | 0.63 | 1.05 | 1.28 | 0.94 | 1.21 | 1.58 | 1.86 | 1.20 | 1.38 | 2.27 | 2.71 | 1.64 |
Last Updated: February 3, 2026, 8:46 pm
Below is a detailed analysis of the quarterly data for Thyrocare Technologies Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 182.00 Cr.. The value appears to be declining and may need further review. It has decreased from 202.00 Cr. (Sep 2025) to 182.00 Cr., marking a decrease of 20.00 Cr..
- For Expenses, as of Dec 2025, the value is 124.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 133.00 Cr. (Sep 2025) to 124.00 Cr., marking a decrease of 9.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 69.00 Cr. (Sep 2025) to 58.00 Cr., marking a decrease of 11.00 Cr..
- For OPM %, as of Dec 2025, the value is 32.00%. The value appears to be declining and may need further review. It has decreased from 34.00% (Sep 2025) to 32.00%, marking a decrease of 2.00%.
- For Other Income, as of Dec 2025, the value is -3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Sep 2025) to -3.00 Cr., marking a decrease of 5.00 Cr..
- For Interest, as of Dec 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.00 Cr. (Sep 2025) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Dec 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Sep 2025) to 20.00 Cr., marking an increase of 10.00 Cr..
- For Profit before tax, as of Dec 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 61.00 Cr. (Sep 2025) to 37.00 Cr., marking a decrease of 24.00 Cr..
- For Tax %, as of Dec 2025, the value is 29.00%. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 29.00%.
- For Net Profit, as of Dec 2025, the value is 26.00 Cr.. The value appears to be declining and may need further review. It has decreased from 43.00 Cr. (Sep 2025) to 26.00 Cr., marking a decrease of 17.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is 1.64. The value appears to be declining and may need further review. It has decreased from 2.71 (Sep 2025) to 1.64, marking a decrease of 1.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:30 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 150 | 180 | 235 | 298 | 332 | 370 | 401 | 474 | 562 | 486 | 524 | 633 | 708 |
| Expenses | 81 | 109 | 140 | 182 | 193 | 222 | 233 | 304 | 330 | 371 | 388 | 446 | 486 |
| Operating Profit | 69 | 71 | 95 | 115 | 139 | 148 | 168 | 171 | 232 | 115 | 136 | 188 | 221 |
| OPM % | 46% | 40% | 40% | 39% | 42% | 40% | 42% | 36% | 41% | 24% | 26% | 30% | 31% |
| Other Income | 7 | 13 | 6 | -16 | 21 | 14 | -35 | 12 | 7 | 5 | 6 | 13 | 14 |
| Interest | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 3 | 5 | 5 | 3 | 2 |
| Depreciation | 6 | 11 | 11 | 12 | 12 | 14 | 20 | 21 | 28 | 34 | 39 | 47 | 46 |
| Profit before tax | 69 | 73 | 89 | 87 | 148 | 147 | 112 | 161 | 207 | 81 | 98 | 151 | 188 |
| Tax % | 33% | 33% | 34% | 46% | 35% | 35% | 29% | 26% | 27% | 30% | 28% | 37% | |
| Net Profit | 46 | 49 | 59 | 47 | 96 | 95 | 79 | 120 | 152 | 57 | 71 | 96 | 120 |
| EPS in Rs | 14.07 | 3.25 | 3.64 | 2.90 | 5.96 | 6.01 | 5.00 | 7.55 | 9.58 | 3.59 | 4.48 | 6.02 | 7.56 |
| Dividend Payout % | 0% | 157% | 91% | 115% | 56% | 111% | 33% | 110% | 52% | 167% | 134% | 116% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 6.52% | 20.41% | -20.34% | 104.26% | -1.04% | -16.84% | 51.90% | 26.67% | -62.50% | 24.56% | 35.21% |
| Change in YoY Net Profit Growth (%) | 0.00% | 13.89% | -40.75% | 124.59% | -105.30% | -15.80% | 68.74% | -25.23% | -89.17% | 87.06% | 10.65% |
Thyrocare Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 10% |
| 3 Years: | 4% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | -3% |
| 3 Years: | -15% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 27% |
| 1 Year: | 55% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 19% |
| 3 Years: | 14% |
| Last Year: | 17% |
Last Updated: September 5, 2025, 1:46 pm
Balance Sheet
Last Updated: January 7, 2026, 4:33 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 51 | 54 | 54 | 54 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
| Reserves | 195 | 229 | 322 | 364 | 400 | 403 | 325 | 393 | 468 | 468 | 461 | 484 | 463 |
| Borrowings | 25 | 0 | 0 | 0 | 0 | 0 | 9 | 10 | 21 | 21 | 39 | 23 | 22 |
| Other Liabilities | 14 | 14 | 39 | 26 | 31 | 32 | 55 | 73 | 55 | 70 | 68 | 116 | 113 |
| Total Liabilities | 246 | 293 | 414 | 444 | 485 | 488 | 442 | 528 | 597 | 612 | 620 | 676 | 651 |
| Fixed Assets | 87 | 83 | 93 | 89 | 103 | 108 | 112 | 119 | 149 | 157 | 159 | 158 | 160 |
| CWIP | 6 | 6 | 1 | 2 | 0 | 1 | 4 | 8 | 2 | 1 | 1 | 14 | 3 |
| Investments | 119 | 162 | 266 | 299 | 315 | 289 | 239 | 274 | 259 | 274 | 291 | 284 | 265 |
| Other Assets | 33 | 42 | 55 | 54 | 68 | 89 | 88 | 127 | 186 | 180 | 169 | 221 | 223 |
| Total Assets | 246 | 293 | 414 | 444 | 485 | 488 | 442 | 528 | 597 | 612 | 620 | 676 | 651 |
Below is a detailed analysis of the balance sheet data for Thyrocare Technologies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 53.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 53.00 Cr..
- For Reserves, as of Sep 2025, the value is 463.00 Cr.. The value appears to be declining and may need further review. It has decreased from 484.00 Cr. (Mar 2025) to 463.00 Cr., marking a decrease of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 22.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 23.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 113.00 Cr.. The value appears to be improving (decreasing). It has decreased from 116.00 Cr. (Mar 2025) to 113.00 Cr., marking a decrease of 3.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 651.00 Cr.. The value appears to be improving (decreasing). It has decreased from 676.00 Cr. (Mar 2025) to 651.00 Cr., marking a decrease of 25.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 158.00 Cr. (Mar 2025) to 160.00 Cr., marking an increase of 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 11.00 Cr..
- For Investments, as of Sep 2025, the value is 265.00 Cr.. The value appears to be declining and may need further review. It has decreased from 284.00 Cr. (Mar 2025) to 265.00 Cr., marking a decrease of 19.00 Cr..
- For Other Assets, as of Sep 2025, the value is 223.00 Cr.. The value appears strong and on an upward trend. It has increased from 221.00 Cr. (Mar 2025) to 223.00 Cr., marking an increase of 2.00 Cr..
- For Total Assets, as of Sep 2025, the value is 651.00 Cr.. The value appears to be declining and may need further review. It has decreased from 676.00 Cr. (Mar 2025) to 651.00 Cr., marking a decrease of 25.00 Cr..
Notably, the Reserves (463.00 Cr.) exceed the Borrowings (22.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 44.00 | 71.00 | 95.00 | 115.00 | 139.00 | 148.00 | 159.00 | 161.00 | 211.00 | 94.00 | 97.00 | 165.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12 | 9 | 11 | 7 | 10 | 11 | 14 | 34 | 60 | 63 | 28 | 40 |
| Inventory Days | 54 | 47 | 54 | 64 | 66 | 54 | 60 | 50 | 54 | 63 | 106 | 93 |
| Days Payable | 13 | 5 | 8 | 4 | 23 | 19 | 62 | 48 | 30 | 52 | 83 | 141 |
| Cash Conversion Cycle | 53 | 51 | 57 | 68 | 53 | 46 | 12 | 37 | 84 | 74 | 51 | -9 |
| Working Capital Days | 22 | 52 | 15 | 28 | 11 | 4 | -12 | 7 | 45 | 34 | 14 | 18 |
| ROCE % | 33% | 27% | 27% | 29% | 33% | 31% | 36% | 37% | 41% | 15% | 18% | 26% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 5,167,803 | 0.34 | 230.33 | 1,722,601 | 2025-12-15 03:04:08 | 200% |
| Nippon India Pharma Fund | 4,392,120 | 2.37 | 195.76 | 1,548,692 | 2025-12-14 07:13:13 | 183.6% |
| HSBC Midcap Fund | 4,373,100 | 1.57 | 194.91 | 950,000 | 2025-12-14 07:13:13 | 360.33% |
| Aditya Birla Sun Life ELSS Tax Saver Fund | 2,873,886 | 0.83 | 128.09 | 1,033,015 | 2025-12-14 07:13:13 | 178.2% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 2,804,472 | 1.94 | 125 | 934,824 | 2025-12-14 07:13:13 | 200% |
| ICICI Prudential Dividend Yield Equity Fund | 1,909,800 | 1.33 | 85.12 | 636,600 | 2025-12-14 04:15:52 | 200% |
| HSBC Large & Mid Cap Fund | 1,737,570 | 1.66 | 77.44 | 434,594 | 2025-12-15 01:20:14 | 299.81% |
| ICICI Prudential Innovation Fund - Direct Fund | 1,652,729 | 0.98 | 73.66 | N/A | N/A | N/A |
| ICICI Prudential Multicap Fund | 1,311,450 | 0.36 | 58.45 | 437,150 | 2025-12-14 07:13:13 | 200% |
| HDFC Pharma and Healthcare Fund | 719,111 | 1.62 | 32.05 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 17.13 | 13.42 | 12.16 | 33.30 | 21.41 |
| Diluted EPS (Rs.) | 17.08 | 13.40 | 12.14 | 33.25 | 21.37 |
| Cash EPS (Rs.) | 27.83 | 21.93 | 19.25 | 39.73 | 27.14 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 103.18 | 99.65 | 101.12 | 99.54 | 80.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 103.18 | 99.65 | 101.12 | 99.54 | 80.81 |
| Revenue From Operations / Share (Rs.) | 129.71 | 108.00 | 99.50 | 111.32 | 93.55 |
| PBDIT / Share (Rs.) | 38.72 | 27.72 | 24.27 | 49.93 | 34.74 |
| PBIT / Share (Rs.) | 28.29 | 18.85 | 16.96 | 43.53 | 29.02 |
| PBT / Share (Rs.) | 27.72 | 18.05 | 16.51 | 43.08 | 28.85 |
| Net Profit / Share (Rs.) | 17.40 | 13.05 | 11.94 | 33.33 | 21.41 |
| NP After MI And SOA / Share (Rs.) | 17.27 | 13.36 | 12.16 | 33.30 | 21.40 |
| PBDIT Margin (%) | 29.85 | 25.66 | 24.39 | 44.85 | 37.13 |
| PBIT Margin (%) | 21.81 | 17.44 | 17.04 | 39.10 | 31.01 |
| PBT Margin (%) | 21.36 | 16.71 | 16.59 | 38.70 | 30.83 |
| Net Profit Margin (%) | 13.41 | 12.08 | 11.99 | 29.94 | 22.89 |
| NP After MI And SOA Margin (%) | 13.31 | 12.37 | 12.22 | 29.91 | 22.87 |
| Return on Networth / Equity (%) | 16.73 | 13.43 | 12.04 | 33.45 | 26.48 |
| Return on Capital Employeed (%) | 26.26 | 18.03 | 16.15 | 42.39 | 34.03 |
| Return On Assets (%) | 13.20 | 10.98 | 10.17 | 28.98 | 20.73 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 1.03 | 0.89 | 0.79 | 0.98 | 0.94 |
| Current Ratio (X) | 2.77 | 3.08 | 3.54 | 4.18 | 2.50 |
| Quick Ratio (X) | 2.39 | 2.55 | 3.18 | 3.80 | 2.26 |
| Inventory Turnover Ratio (X) | 14.62 | 4.38 | 5.82 | 6.80 | 7.44 |
| Dividend Payout Ratio (NP) (%) | 104.15 | 134.63 | 123.29 | 45.02 | 46.69 |
| Dividend Payout Ratio (CP) (%) | 64.93 | 80.89 | 76.98 | 37.76 | 36.84 |
| Earning Retention Ratio (%) | -4.15 | -34.63 | -23.29 | 54.98 | 53.31 |
| Cash Earning Retention Ratio (%) | 35.07 | 19.11 | 23.02 | 62.24 | 63.16 |
| Interest Coverage Ratio (X) | 67.28 | 34.95 | 54.67 | 111.45 | 211.14 |
| Interest Coverage Ratio (Post Tax) (X) | 31.23 | 17.45 | 27.89 | 75.40 | 131.14 |
| Enterprise Value (Cr.) | 3550.20 | 3118.27 | 2246.85 | 4079.23 | 4758.17 |
| EV / Net Operating Revenue (X) | 5.17 | 5.45 | 4.27 | 6.93 | 9.62 |
| EV / EBITDA (X) | 17.30 | 21.24 | 17.49 | 15.44 | 25.90 |
| MarketCap / Net Operating Revenue (X) | 5.24 | 5.48 | 4.32 | 6.95 | 9.65 |
| Retention Ratios (%) | -4.15 | -34.63 | -23.29 | 54.97 | 53.30 |
| Price / BV (X) | 6.59 | 5.95 | 4.26 | 7.77 | 11.17 |
| Price / Net Operating Revenue (X) | 5.24 | 5.48 | 4.32 | 6.95 | 9.65 |
| EarningsYield | 0.02 | 0.02 | 0.02 | 0.04 | 0.02 |
After reviewing the key financial ratios for Thyrocare Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 17.13. This value is within the healthy range. It has increased from 13.42 (Mar 24) to 17.13, marking an increase of 3.71.
- For Diluted EPS (Rs.), as of Mar 25, the value is 17.08. This value is within the healthy range. It has increased from 13.40 (Mar 24) to 17.08, marking an increase of 3.68.
- For Cash EPS (Rs.), as of Mar 25, the value is 27.83. This value is within the healthy range. It has increased from 21.93 (Mar 24) to 27.83, marking an increase of 5.90.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 103.18. It has increased from 99.65 (Mar 24) to 103.18, marking an increase of 3.53.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 103.18. It has increased from 99.65 (Mar 24) to 103.18, marking an increase of 3.53.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 129.71. It has increased from 108.00 (Mar 24) to 129.71, marking an increase of 21.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 38.72. This value is within the healthy range. It has increased from 27.72 (Mar 24) to 38.72, marking an increase of 11.00.
- For PBIT / Share (Rs.), as of Mar 25, the value is 28.29. This value is within the healthy range. It has increased from 18.85 (Mar 24) to 28.29, marking an increase of 9.44.
- For PBT / Share (Rs.), as of Mar 25, the value is 27.72. This value is within the healthy range. It has increased from 18.05 (Mar 24) to 27.72, marking an increase of 9.67.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 17.40. This value is within the healthy range. It has increased from 13.05 (Mar 24) to 17.40, marking an increase of 4.35.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 17.27. This value is within the healthy range. It has increased from 13.36 (Mar 24) to 17.27, marking an increase of 3.91.
- For PBDIT Margin (%), as of Mar 25, the value is 29.85. This value is within the healthy range. It has increased from 25.66 (Mar 24) to 29.85, marking an increase of 4.19.
- For PBIT Margin (%), as of Mar 25, the value is 21.81. This value exceeds the healthy maximum of 20. It has increased from 17.44 (Mar 24) to 21.81, marking an increase of 4.37.
- For PBT Margin (%), as of Mar 25, the value is 21.36. This value is within the healthy range. It has increased from 16.71 (Mar 24) to 21.36, marking an increase of 4.65.
- For Net Profit Margin (%), as of Mar 25, the value is 13.41. This value exceeds the healthy maximum of 10. It has increased from 12.08 (Mar 24) to 13.41, marking an increase of 1.33.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.31. This value is within the healthy range. It has increased from 12.37 (Mar 24) to 13.31, marking an increase of 0.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is 16.73. This value is within the healthy range. It has increased from 13.43 (Mar 24) to 16.73, marking an increase of 3.30.
- For Return on Capital Employeed (%), as of Mar 25, the value is 26.26. This value is within the healthy range. It has increased from 18.03 (Mar 24) to 26.26, marking an increase of 8.23.
- For Return On Assets (%), as of Mar 25, the value is 13.20. This value is within the healthy range. It has increased from 10.98 (Mar 24) to 13.20, marking an increase of 2.22.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.04 (Mar 24) to 0.00, marking a decrease of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.03. It has increased from 0.89 (Mar 24) to 1.03, marking an increase of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 2.77. This value is within the healthy range. It has decreased from 3.08 (Mar 24) to 2.77, marking a decrease of 0.31.
- For Quick Ratio (X), as of Mar 25, the value is 2.39. This value exceeds the healthy maximum of 2. It has decreased from 2.55 (Mar 24) to 2.39, marking a decrease of 0.16.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.62. This value exceeds the healthy maximum of 8. It has increased from 4.38 (Mar 24) to 14.62, marking an increase of 10.24.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 104.15. This value exceeds the healthy maximum of 50. It has decreased from 134.63 (Mar 24) to 104.15, marking a decrease of 30.48.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 64.93. This value exceeds the healthy maximum of 50. It has decreased from 80.89 (Mar 24) to 64.93, marking a decrease of 15.96.
- For Earning Retention Ratio (%), as of Mar 25, the value is -4.15. This value is below the healthy minimum of 40. It has increased from -34.63 (Mar 24) to -4.15, marking an increase of 30.48.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 35.07. This value is below the healthy minimum of 40. It has increased from 19.11 (Mar 24) to 35.07, marking an increase of 15.96.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 67.28. This value is within the healthy range. It has increased from 34.95 (Mar 24) to 67.28, marking an increase of 32.33.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 31.23. This value is within the healthy range. It has increased from 17.45 (Mar 24) to 31.23, marking an increase of 13.78.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,550.20. It has increased from 3,118.27 (Mar 24) to 3,550.20, marking an increase of 431.93.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.17. This value exceeds the healthy maximum of 3. It has decreased from 5.45 (Mar 24) to 5.17, marking a decrease of 0.28.
- For EV / EBITDA (X), as of Mar 25, the value is 17.30. This value exceeds the healthy maximum of 15. It has decreased from 21.24 (Mar 24) to 17.30, marking a decrease of 3.94.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has decreased from 5.48 (Mar 24) to 5.24, marking a decrease of 0.24.
- For Retention Ratios (%), as of Mar 25, the value is -4.15. This value is below the healthy minimum of 30. It has increased from -34.63 (Mar 24) to -4.15, marking an increase of 30.48.
- For Price / BV (X), as of Mar 25, the value is 6.59. This value exceeds the healthy maximum of 3. It has increased from 5.95 (Mar 24) to 6.59, marking an increase of 0.64.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has decreased from 5.48 (Mar 24) to 5.24, marking a decrease of 0.24.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Thyrocare Technologies Ltd:
- Net Profit Margin: 13.41%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 26.26% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.73% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 31.23
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.39
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 49.7 (Industry average Stock P/E: 88.7)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.41%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | D/37-1, TTC Industrial Area, MIDC, Turbhe, New Mumbai Maharashtra 400703 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rahul Guha | Managing Director & CEO |
| Mr. Dharmil Sheth | Non Executive Director |
| Mr. Hardik Dedhia | Non Executive Director |
| Dr. Dhaval Shah | Non Executive Director |
| Dr.(Mrs.) Indumati Gopinathan | Independent Director |
| Dr.(Ms.) Prapti Gilada | Independent Director |
| Dr. Harshil Vora | Independent Director |
| Mr. Nishant A Shah | Independent Director |
| Mr. Anandh Sundar | Independent Director |
FAQ
What is the intrinsic value of Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd's intrinsic value (as of 10 February 2026) is ₹217.42 which is 47.23% lower the current market price of ₹412.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹6,529 Cr. market cap, FY2025-2026 high/low of ₹538/219, reserves of ₹463 Cr, and liabilities of ₹651 Cr.
What is the Market Cap of Thyrocare Technologies Ltd?
The Market Cap of Thyrocare Technologies Ltd is 6,529 Cr..
What is the current Stock Price of Thyrocare Technologies Ltd as on 10 February 2026?
The current stock price of Thyrocare Technologies Ltd as on 10 February 2026 is ₹412.
What is the High / Low of Thyrocare Technologies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Thyrocare Technologies Ltd stocks is ₹538/219.
What is the Stock P/E of Thyrocare Technologies Ltd?
The Stock P/E of Thyrocare Technologies Ltd is 49.7.
What is the Book Value of Thyrocare Technologies Ltd?
The Book Value of Thyrocare Technologies Ltd is 32.4.
What is the Dividend Yield of Thyrocare Technologies Ltd?
The Dividend Yield of Thyrocare Technologies Ltd is 1.70 %.
What is the ROCE of Thyrocare Technologies Ltd?
The ROCE of Thyrocare Technologies Ltd is 26.5 %.
What is the ROE of Thyrocare Technologies Ltd?
The ROE of Thyrocare Technologies Ltd is 17.4 %.
What is the Face Value of Thyrocare Technologies Ltd?
The Face Value of Thyrocare Technologies Ltd is 10.0.